| Literature DB >> 31704880 |
Taishi Onodera1, Kana Hashi1, Rajni Kant Shukla1, Motohiro Miki2,3, Reiko Takai-Todaka2, Akira Fujimoto2, Masayuki Kuraoka4, Tatsuya Miyoshi5, Kazuo Kobayashi6, Hideki Hasegawa7, Manabu Ato1, Garnett Kelsoe4, Kazuhiko Katayama2, Yoshimasa Takahashi8.
Abstract
Virus-like particles (VLPs) provide a well-established vaccine platform; however, the immunogenic properties acquired by VLP structure remain poorly understood. In this study, we showed that systemic vaccination with norovirus VLP recalls human IgA responses at higher magnitudes than IgG responses under a humanized mouse model that was established by introducing human PBMCs in severely immunodeficient mice. The recall responses elicited by VLP vaccines depended on VLP structure and the disruption of VLP attenuated recall responses, with a more profound reduction being observed in IgA responses. The IgA-focusing property was also conserved in a murine norovirus-primed model under which murine IgA responses were recalled in a manner dependent on VLP structure. Importantly, the VLP-driven IgA response preferentially targeted virus-neutralizing epitopes located in the receptor-binding domain. Consequently, VLP-driven IgA responses were qualitatively superior to IgG responses in terms of the virus-neutralizing activity in vitro. Furthermore, the IgA in mucosa obtained remarkable protective function toward orally administrated virus in vivo. Thus, our results indicate the immune-focusing properties of the VLP vaccine that improve the quality/quantity of mucosal IgA responses, a finding with important implications for developing mucosal vaccines.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31704880 PMCID: PMC6900486 DOI: 10.4049/jimmunol.1900481
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422